Sanofi to invest $40 million at an as-converted price of $7.44 per share of common stock-
- Sanofi to receive an exclusive right of first negotiation for license of Company’s small molecule TREM2 agonist program, including VG-3927, currently in phase 1 clinical studies -
- Company expects proceeds to extend cash runway into 2026 -
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.